ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for monitor Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.

ABCL AbCellera Biologics Inc

2.94
0.06 (2.08%)
Last Updated: 16:35:20
Delayed by 15 minutes
Share Name Share Symbol Market Type
AbCellera Biologics Inc NASDAQ:ABCL NASDAQ Common Stock
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.06 2.08% 2.94 2.94 2.95 3.0201 2.87 2.87 1,011,528 16:35:20

AbCellera to Present at the Jefferies London Healthcare Conference on November 14, 2023

31/10/2023 8:05pm

Business Wire


AbCellera Biologics (NASDAQ:ABCL)
Historical Stock Chart


From Jun 2023 to Jun 2024

Click Here for more AbCellera Biologics Charts.

AbCellera (Nasdaq: ABCL) today announced that executives from the Company will present at the Jefferies London Healthcare Conference on Tuesday, November 14, 2023, at 4:30 p.m. Greenwich Mean Time (8:30 a.m. Pacific Time).

A live audio webcast of the presentation may be accessed through a link that will be posted on AbCellera's Investor Relations website. A replay will be available through the same link following the presentation.

About AbCellera Biologics Inc. AbCellera is breaking the barriers of conventional antibody discovery to bring better medicines to patients, sooner. AbCellera’s engine integrates expert teams, technology, and facilities with the data science and automation needed to propel antibody-based medicines from target to clinic in nearly every therapeutic area with precision and speed. AbCellera provides innovative biotechs and leading pharmaceutical companies with a competitive advantage that empowers them to move quickly, reduce cost, and tackle the toughest problems in drug development. For more information, please visit www.abcellera.com.

Inquiries Media: Jessica Yingling, Ph.D.; media@abcellera.com, +1(236)521-6774 Business Development: Murray McCutcheon, Ph.D.; bd@abcellera.com, +1(604)559-9005 Investor Relations: Josephine Hellschlienger, Ph.D.; ir@abcellera.com, +1(778)729-9116

1 Year AbCellera Biologics Chart

1 Year AbCellera Biologics Chart

1 Month AbCellera Biologics Chart

1 Month AbCellera Biologics Chart

Your Recent History

Delayed Upgrade Clock